Download PDF

1. Company Snapshot

1.a. Company Description

West Pharmaceutical Services, Inc.designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.It operates in two segments, Proprietary Products and Contract-Manufactured Products.


The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.This segment serves biologic, generic, and pharmaceutical drug companies.


The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.It serves pharmaceutical, diagnostic, and medical device companies.The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors.


West Pharmaceutical Services, Inc.was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

Show Full description

1.b. Last Insights on WST

West Pharmaceutical Services, Inc.'s recent performance was negatively impacted by selling pressure from institutional investors, including Bank of New York Mellon Corp, which reduced its position by 9.4%, and Candriam S.C.A., which lowered its stake by 8.6%. Additionally, Fisher Asset Management LLC and ProShare Advisors LLC also decreased their holdings. However, some investors, such as Rockland Trust Co., increased their stake. The company's focus on high-value proprietary elastomer components and secular industry drivers, like GLP-1 demand, underpins robust margin and revenue growth (Source: Marketbeat).

1.c. Company Highlights

2. West Pharmaceutical Services' Strong Q4 2025 Earnings Beat Expectations

West Pharmaceutical Services delivered a robust fourth quarter in 2025, with revenues reaching $850 million, exceeding expectations and marking a 7.5% reported and 3.3% organic growth. The company's adjusted operating margins stood at 21.4%, while adjusted EPS of $2.04 surged 12% compared to the prior year, significantly beating analyst estimates of $1.83. Free cash flow in the quarter was $175 million, more than double the prior-year level. The strong financial performance was driven by the growth in high-value product (HVP) components, which rose over 15% in the fourth quarter and 9% for the full year 2025.

Publication Date: Feb -17

📋 Highlights
  • Q4 Revenue Exceeds Expectations: Net sales reached $850M, up 7.5% reported and 3.3% organically, with adjusted EPS of $2.04 (12% YoY growth).
  • HVP Components Drive Growth: High-value product (HVP) components grew 15% in Q4, contributing 9% annual growth, fueled by biologics, Annex 1 compliance, and GLP-1 demand.
  • Free Cash Flow Doubles: Q4 free cash flow surged to $175M, a 70% increase YoY, while operating margins hit 21.4%.
  • 2026 Guidance Set: Revenue projected at $3.215B–$3.275B (4.6–6.5% growth), with adjusted EPS of $7.85–$8.20 (double-digit growth at midpoint).
  • Capacity Expansion Focus: Prioritizing HVP components capacity growth, particularly in Europe and U.S., to meet rising demand, with non-GLP-1 HVP expected to drive 5–7% organic growth in 2026.

Drivers of Growth

The growth in HVP components was fueled by three key drivers: the rise of biologics and biosimilars, increasing global regulatory requirements such as Annex 1, and the expanding GLP-1 market. The company continues to address customer needs through scientific support and innovation, exemplified by the launch of the West Synchrony prefillable syringe system. As Eric M. Green mentioned, the company is seeing positive momentum driven by key growth drivers and is optimistic about the future.

Outlook for 2026

West Pharmaceutical Services expects 2026 to have a more broad-based growth profile, driven by non-GLP-1 HVP components growing high single digit to low double digits. The company anticipates revenue to be in the range of $3.215 billion to $3.275 billion, representing reported growth of 4.6% to 6.5% and organic growth of 5% to 7%. Analysts estimate next year's revenue growth at 6.1%, aligning with the company's guidance.

Valuation

With a P/E Ratio of 36.68 and an EV/EBITDA of 24.47, the market appears to be pricing in significant growth expectations. The company's ROE of 17.41% and ROIC of 13.27% indicate strong profitability. As West Pharmaceutical Services continues to invest in its high-value product components and expand its capacity, its robust momentum and optimistic outlook for 2026 position it well for future growth.

3. NewsRoom

Card image cap

ALGN vs. WST: Which Stock Is the Better Value Option?

Mar -03

Source: zacks.com

Card image cap

Reviewing West Pharmaceutical Services (NYSE:WST) and Henry Schein (NASDAQ:HSIC)

Mar -02

Source: defenseworld.net

Card image cap

West to Participate in Upcoming Investor Conferences

Feb -27

Source: prnewswire.com

Card image cap

Artisan Partners Limited Partnership Increases Stake in West Pharmaceutical Services, Inc. $WST

Feb -27

Source: defenseworld.net

Card image cap

Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 32.33%: Read This Before Placing a Bet

Feb -23

Source: zacks.com

Card image cap

West Announces Quarterly Dividend and Share Repurchase Program

Feb -17

Source: prnewswire.com

Card image cap

West Pharmaceutical's Under-the-Radar Dividend Worth Watching

Feb -15

Source: 247wallst.com

Card image cap

Cibc World Market Inc. Has $4.88 Million Holdings in West Pharmaceutical Services, Inc. $WST

Feb -15

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.37%)

6. Segments

Proprietary Products

Expected Growth: 5%

West Pharmaceutical Services, Inc.'s proprietary products growth is driven by increasing demand for high-value injectable drugs, growing adoption of self-administered injectable devices, and expansion into emerging markets. Additionally, the company's innovative product portfolio, including Daikyo Crystal Zenith and NovaPure components, supports growth through partnerships with leading pharmaceutical companies.

Contract-Manufactured Products

Expected Growth: 7%

West Pharmaceutical Services, Inc.'s 7% growth in Contract-Manufactured Products is driven by increasing demand for injectable drugs, rising adoption of prefilled syringes and cartridges, and growing need for pharmaceutical packaging solutions. Additionally, the company's strategic partnerships, capacity expansions, and investments in advanced manufacturing technologies are contributing to its growth momentum.

7. Detailed Products

NovaPure Stopper

A high-quality, ready-to-use stopper designed for use in lyophilization and other pharmaceutical applications

FluroTec Stoppers

A line of fluoropolymer-coated stoppers designed for use in pharmaceutical and biotechnology applications

Westar RS Stoppers

A line of ready-to-use, sterilized stoppers designed for use in pharmaceutical and biotechnology applications

Daikyo Crystal Zenith Stoppers

A line of high-quality, ready-to-use stoppers designed for use in pharmaceutical and biotechnology applications

Self-Sealing Stoppers

A line of self-sealing stoppers designed for use in pharmaceutical and biotechnology applications

Vial Containment Solutions

A line of vial containment solutions designed for use in pharmaceutical and biotechnology applications

Syringe Containment Solutions

A line of syringe containment solutions designed for use in pharmaceutical and biotechnology applications

Cartridge Containment Solutions

A line of cartridge containment solutions designed for use in pharmaceutical and biotechnology applications

Contract Manufacturing Services

A range of contract manufacturing services designed to support pharmaceutical and biotechnology companies

Analytical Services

A range of analytical services designed to support pharmaceutical and biotechnology companies

8. West Pharmaceutical Services, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

West Pharmaceutical Services, Inc. operates in a niche market with high barriers to entry, reducing the threat of substitutes. However, the company's products are not entirely unique, and some customers may find alternative solutions.

Bargaining Power Of Customers

West Pharmaceutical Services, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical components of customers' manufacturing processes, making it difficult for customers to negotiate prices.

Bargaining Power Of Suppliers

West Pharmaceutical Services, Inc. relies on a few key suppliers for certain raw materials, which gives these suppliers some bargaining power. However, the company's large scale and diversified supply chain mitigate this risk.

Threat Of New Entrants

The pharmaceutical packaging industry has high barriers to entry, including significant capital expenditures and regulatory hurdles. This makes it difficult for new entrants to compete with established players like West Pharmaceutical Services, Inc.

Intensity Of Rivalry

The pharmaceutical packaging industry is highly competitive, with several established players competing for market share. West Pharmaceutical Services, Inc. must continually innovate and invest in R&D to maintain its market position.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 9.69%
Debt Cost 3.95%
Equity Weight 90.31%
Equity Cost 9.14%
WACC 8.63%
Leverage 10.73%

11. Quality Control: West Pharmaceutical Services, Inc. passed 9 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Abbott

A-Score: 6.3/10

Value: 2.8

Growth: 5.9

Quality: 7.8

Yield: 4.0

Momentum: 7.5

Volatility: 9.7

1-Year Total Return ->

View Full Report
Stock-Card
ResMed

A-Score: 5.7/10

Value: 2.1

Growth: 8.1

Quality: 8.7

Yield: 1.0

Momentum: 6.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Thermo Fisher

A-Score: 4.8/10

Value: 1.7

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 7.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Becton Dickinson

A-Score: 4.6/10

Value: 3.3

Growth: 4.6

Quality: 5.2

Yield: 4.0

Momentum: 2.5

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Intuitive Surgical

A-Score: 4.6/10

Value: 0.0

Growth: 6.7

Quality: 7.4

Yield: 0.0

Momentum: 7.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
West Pharma

A-Score: 3.7/10

Value: 1.0

Growth: 6.1

Quality: 7.4

Yield: 0.0

Momentum: 3.5

Volatility: 4.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

251.38$

Current Price

251.38$

Potential

-0.00%

Expected Cash-Flows